Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.

Literature DB >> 26957559

Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.

Kurt A Schalper¹, Edward Kaftan², Roy S Herbst³.

Abstract

Blockade of the PD-1 axis has emerged as an effective anticancer immunotherapy against various tumor types. Diverse studies have identified biomarkers associated with response to these therapies. However, the clinical use of such tests is limited by their variable performance and restricted understanding of their biologic significance. Clin Cancer Res; 22(9); 2102-4. ©2016 AACRSee related article by Ock et al., p. 2261. ©2016 American Association for Cancer Research.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2016 PMID： 26957559 PMCID： PMC4940186 DOI： 10.1158/1078-0432.CCR-16-0169

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

14 in total

1. Nivolumab in previously untreated melanoma without BRAF mutation.

Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors: Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal: Lancet Date: 2015-12-19 Impact factor: 79.321

3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal: Nature Date: 2014-11-27 Impact factor: 49.962

4. Molecular and genetic properties of tumors associated with local immune cytolytic activity.

Authors: Michael S Rooney; Sachet A Shukla; Catherine J Wu; Gad Getz; Nir Hacohen
Journal: Cell Date: 2015-01-15 Impact factor: 41.582

5. The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors: Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors: Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245

8. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245

9. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

Authors: Joseph McLaughlin; Gang Han; Kurt A Schalper; Daniel Carvajal-Hausdorf; Vasiliki Pelekanou; Jamaal Rehman; Vamsidhar Velcheti; Roy Herbst; Patricia LoRusso; David L Rimm
Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777

10. PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors: Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal: Nature Date: 2014-11-27 Impact factor: 49.962

15 in total

Review 1. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Authors: Deborah B Doroshow; Miguel F Sanmamed; Katherine Hastings; Katerina Politi; David L Rimm; Lieping Chen; Ignacio Melero; Kurt A Schalper; Roy S Herbst
Journal: Clin Cancer Res Date: 2019-03-01 Impact factor: 12.531

Review 2. Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer.

Authors: Benedikt Martin; Bruno Märkl
Journal: Visc Med Date: 2019-02-04

3. Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort.

Authors: Richard J Straker; Katharine Krupp; Cimarron E Sharon; Alexandra S Thaler; Nicholas J Kelly; Emily Y Chu; David E Elder; Xiaowei Xu; John T Miura; Giorgos C Karakousis
Journal: Ann Surg Oncol Date: 2022-03-17 Impact factor: 4.339

Review 4. High-throughput genomic profiling of tumor-infiltrating leukocytes.

Authors: Aaron M Newman; Ash A Alizadeh
Journal: Curr Opin Immunol Date: 2016-06-30 Impact factor: 7.486

5. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Authors: David A Fabrizio; Thomas J George; Richard F Dunne; Garrett Frampton; James Sun; Kyle Gowen; Mark Kennedy; Joel Greenbowe; Alexa B Schrock; Aram F Hezel; Jeffrey S Ross; Phillip J Stephens; Siraj M Ali; Vincent A Miller; Marwan Fakih; Samuel J Klempner
Journal: J Gastrointest Oncol Date: 2018-08

6. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.

Authors: Karima Oualla; Luis Castelo Branco; Lamiae Nouiyakh; Lamiae Amaadour; Zineb Benbrahim; Samia Arifi; Nawfel Mellas
Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302

Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.

1. Nivolumab in previously untreated melanoma without BRAF mutation.

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

4. Molecular and genetic properties of tumors associated with local immune cytolytic activity.

5. The prognostic landscape of genes and infiltrating immune cells across human cancers.

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

8. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

9. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

10. PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Review 1. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Review 2. Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer.

3. Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort.

Review 4. High-throughput genomic profiling of tumor-infiltrating leukocytes.

5. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

6. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.

7. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Review 8. PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.

Review 9. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.

10. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy.

Review 1. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Review 2. Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer.

Review 4. High-throughput genomic profiling of tumor-infiltrating leukocytes.

Review 8. PD-L1 testing, fit for routine evaluation? From a patholo﻿gist's point of view.

Review 9. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.

Review 8. PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.